AMRN
Price
$0.59
Change
-$0.00 (-0.00%)
Updated
Nov 6 closing price
111 days until earnings call
GTBP
Price
$2.99
Change
-$0.00 (-0.00%)
Updated
Nov 6 closing price
Ad is loading...

AMRN vs GTBP

Header iconAMRN vs GTBP Comparison
Open Charts AMRN vs GTBPBanner chart's image
Amarin
Price$0.59
Change-$0.00 (-0.00%)
Volume$916.52K
CapitalizationN/A
GT Biopharma
Price$2.99
Change-$0.00 (-0.00%)
Volume$9.33K
CapitalizationN/A
View a ticker or compare two or three
AMRN vs GTBP Comparison Chart
Loading...
AMRN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GTBP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
AMRN vs. GTBP commentary
Nov 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRN is a StrongSell and GTBP is a Buy.

COMPARISON
Comparison
Nov 08, 2024
Stock price -- (AMRN: $0.59 vs. GTBP: $2.99)
Brand notoriety: AMRN: Notable vs. GTBP: Not notable
AMRN represents the Pharmaceuticals: Major, while GTBP is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: AMRN: 113% vs. GTBP: 52%
Market capitalization -- AMRN: $357.53M vs. GTBP: $6.68M
AMRN [@Pharmaceuticals: Major] is valued at $357.53M. GTBP’s [@Biotechnology] market capitalization is $6.68M. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $486.24B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B. The average market capitalization across the [@Biotechnology] industry is $2.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRN’s FA Score shows that 0 FA rating(s) are green whileGTBP’s FA Score has 1 green FA rating(s).

  • AMRN’s FA Score: 0 green, 5 red.
  • GTBP’s FA Score: 1 green, 4 red.
According to our system of comparison, GTBP is a better buy in the long-term than AMRN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRN’s TA Score shows that 5 TA indicator(s) are bullish while GTBP’s TA Score has 6 bullish TA indicator(s).

  • AMRN’s TA Score: 5 bullish, 4 bearish.
  • GTBP’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, GTBP is a better buy in the short-term than AMRN.

Price Growth

AMRN (@Pharmaceuticals: Major) experienced а -1.64% price change this week, while GTBP (@Biotechnology) price change was -0.66% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.41%. For the same industry, the average monthly price growth was -0.68%, and the average quarterly price growth was +9.03%.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.10%. For the same industry, the average monthly price growth was +12.99%, and the average quarterly price growth was +10.90%.

Reported Earning Dates

AMRN is expected to report earnings on Feb 26, 2025.

GTBP is expected to report earnings on May 13, 2024.

Industries' Descriptions

@Pharmaceuticals: Major (-1.41% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

@Biotechnology (+3.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMRN($358M) has a higher market cap than GTBP($6.68M). AMRN YTD gains are higher at: -31.920 vs. GTBP (-60.915). GTBP has higher annual earnings (EBITDA): -11.35M vs. AMRN (-50.7M). AMRN has more cash in the bank: 321M vs. GTBP (9.25M). GTBP has less debt than AMRN: GTBP (0) vs AMRN (8.74M). AMRN has higher revenues than GTBP: AMRN (307M) vs GTBP (0).
AMRNGTBPAMRN / GTBP
Capitalization358M6.68M5,358%
EBITDA-50.7M-11.35M447%
Gain YTD-31.920-60.91552%
P/E Ratio67.11N/A-
Revenue307M0-
Total Cash321M9.25M3,471%
Total Debt8.74M0-
FUNDAMENTALS RATINGS
AMRN vs GTBP: Fundamental Ratings
AMRN
GTBP
OUTLOOK RATING
1..100
524
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
21
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9198
PRICE GROWTH RATING
1..100
6242
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GTBP's Valuation (21) in the null industry is significantly better than the same rating for AMRN (92) in the Pharmaceuticals Other industry. This means that GTBP’s stock grew significantly faster than AMRN’s over the last 12 months.

GTBP's Profit vs Risk Rating (100) in the null industry is in the same range as AMRN (100) in the Pharmaceuticals Other industry. This means that GTBP’s stock grew similarly to AMRN’s over the last 12 months.

AMRN's SMR Rating (91) in the Pharmaceuticals Other industry is in the same range as GTBP (98) in the null industry. This means that AMRN’s stock grew similarly to GTBP’s over the last 12 months.

GTBP's Price Growth Rating (42) in the null industry is in the same range as AMRN (62) in the Pharmaceuticals Other industry. This means that GTBP’s stock grew similarly to AMRN’s over the last 12 months.

GTBP's P/E Growth Rating (100) in the null industry is in the same range as AMRN (100) in the Pharmaceuticals Other industry. This means that GTBP’s stock grew similarly to AMRN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRNGTBP
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 4 days ago
86%
Declines
ODDS (%)
Bearish Trend 8 days ago
89%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
AMRN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GTBP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BASAX23.681.01
+4.46%
Brown Advisory Small-Cap Growth Adv
CEYRX101.231.16
+1.16%
Calvert Equity R6
MSUSX10.26N/A
N/A
Morgan Stanley Inst US Real Estate I
JEEBX15.06-0.06
-0.40%
JHancock Infrastructure A
HDAVX16.18-0.23
-1.40%
Janus Henderson Responsible Intl Div A

AMRN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMRN has been loosely correlated with KZR. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRN jumps, then KZR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRN
1D Price
Change %
AMRN100%
-4.96%
KZR - AMRN
56%
Loosely correlated
+2.19%
CNTB - AMRN
55%
Loosely correlated
-4.42%
HRTX - AMRN
44%
Loosely correlated
+1.69%
MGNX - AMRN
44%
Loosely correlated
+10.88%
ALXO - AMRN
43%
Loosely correlated
+0.66%
More

GTBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, GTBP has been loosely correlated with PTCT. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if GTBP jumps, then PTCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GTBP
1D Price
Change %
GTBP100%
+3.10%
PTCT - GTBP
35%
Loosely correlated
+5.63%
AMRN - GTBP
33%
Poorly correlated
-4.96%
MDGL - GTBP
32%
Poorly correlated
+0.21%
VKTX - GTBP
31%
Poorly correlated
+1.93%
BPMUF - GTBP
29%
Poorly correlated
N/A
More